Ceritinib Displays Whole Body, Intracranial Efficacy in Crizotinib-treated Patients
Ceritinib treatment demonstrated clinically meaningful whole body and intracranial activity with an acceptable tolerability profile.
ELCC 2016
Brigatinib Shows Antitumor Activity in ALK+ NSCLC
Brigatinib demonstrated antitumor activity in crizotinib-treated and crizotinib-naïve patients with non-small cell lung cancer (NSCLC).
Adding Gefitinib to Pemetrexed, Carboplatin Improves PFS in Lung Adenocarcinoma
The addition of gefitinib to first-line pemetrexed plus carboplatin prolongs progression-free survival compared with chemotherapy alone and gefitinib alone.
Tolerability-guided Dose Adjustment of Afatinib Reduces Adverse Events
Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.
Third-generation EGFR TKI Active in T790M-positive NSCLC
BI 1482694 demonstrated meaningful clinical activity in patients with EGFR TKI-resistant non-small cell lung cancer (NSCLC).
Overtreatment Possible for Clinically Diagnosed Early-stage Lung Cancer
Patients with clinically diagnosed early-stage lung cancer were found to have improved cancer-specific survival.
Study Assesses Associations Between EGFR Mutation Subtypes, Patient Characteristics
Different EGFR mutation subtypes are associated with different clinical and demographic characteristics.
First-line Afatinib Improves PFS vs Gefitinib in Advanced NSCLC
Afatinib significantly prolonged progression-free survival (PFS) for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
Next post in ELCC 2016
